SINEW PHARMA INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57 TWD | +1.06% |
|
+1.79% | -15.81% |
| Mar. 19 | Sinew Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Sinew Pharma Inc.(TPEX:6634) added to S&P Global BMI Index | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 0.33 10.56 | Sales 2023 | - | Capitalization | 4.8B 154B |
|---|---|---|---|---|---|
| Net income 2022 | -140M -4.51B | Net income 2023 | -171M -5.5B | EV / Sales 2022 | 18,117,189,024 x |
| Net cash position 2022 | 1.38B 44.53B | Net cash position 2023 | 1.27B 40.75B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-51.9
x | P/E ratio 2023 |
-27.9
x | Employees | 52 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.06% | ||
| 1 week | +1.79% | ||
| Current month | -0.87% | ||
| 1 month | -9.38% | ||
| 3 months | -16.18% | ||
| 6 months | -19.15% | ||
| Current year | -15.81% |
1 week
52.00
57.20
1 month
52.0061.90
Current year
52.0072.00
1 year
52.0085.50
3 years
52.00141.50
5 years
17.30176.00
10 years
12.95176.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Min Zhu
CEO | Chief Executive Officer | - | 14-06-17 |
Tzu Wen Chen
DFI | Director of Finance/CFO | - | - |
Cheng Hui Hsiung
CTO | Chief Tech/Sci/R&D Officer | - | 14-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Chuan Chen
BRD | Director/Board Member | - | - |
Li Chun Han
BRD | Director/Board Member | 66 | 19-06-26 |
Tu Mu Kuo
BRD | Director/Board Member | - | 19-06-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 57 | +1.06% | 132 648 |
| 24-05-16 | 56.4 | +4.64% | 206,415 |
| 24-05-15 | 53.9 | -2.53% | 84,048 |
| 24-05-14 | 55.3 | +0.36% | 20,647 |
| 24-05-13 | 55.1 | -0.36% | 30,518 |
End-of-day quote Taipei Exchange, May 16, 2024
More quotes
Sinew Pharma Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of liver disease treatment drugs and pain medication. The Company's main products include fatty liver disease treatment drugs SNP-610, SNP-630, no hepatotoxicity painkillers SNP-810 and antidote SNP-820. The Company's products are in clinical trials.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.81% | 125M | |
| +35.09% | 50.85B | |
| +0.59% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.71% | 26.11B | |
| -21.68% | 19.13B | |
| +8.63% | 13.05B | |
| +26.96% | 12.16B | |
| +24.41% | 12.08B |
- Stock Market
- Equities
- 6634 Stock